Medical News

RSS

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Advanced Pain Remedies, a subsidiary of Cato BioVentures, announces that a three million dollar grant has been received, to advance its lead development candidate, SP-SAP. Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases, has been awarded a $3 million grant from the National Cancer Institute (NCI).

10 Jan 2011

House postpones repeal vote, tones down rhetoric

House Republicans have called off [this] week's legislative action, including a planned Wednesday vote on a GOP bill to repeal President Obama's health care law, because of today's shooting attack on Rep. Gabrielle Giffords, D-Ariz., and others in Tucson. Giffords supported the law (Davis and House, 1/8).

10 Jan 2011

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

Vicept Therapeutics, Inc. announced positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.

10 Jan 2011

OpEds: Health reform repeal; CBO's numbers; Reviving public option?

[A]s a political matter, an outright repeal isn't really a winner. Most Americans dislike the law, but few are gunning to do away with it altogether. They don't like its mandates and costs, but they'd prefer to see a scaled down law that still provides more access to health care. Republicans run the risk of overreaching on this, as Democrats did in pushing a vast expansion of government into the health care field.

10 Jan 2011

T2 Biosystems relocates to new 20,000 sq.ft. facility in Lexington

T2 Biosystems, Inc., a company developing next-generation medical diagnostic products, today announced that it has relocated to a newly renovated 20,000 sq.ft. facility located in Lexington, MA.

10 Jan 2011

ACADIA raises $15 million through private placement

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterprise Associates and Venrock.

10 Jan 2011

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical Sealant.

10 Jan 2011

Neuroptix announces closing of $4 million Series C funding round

Neuroptix Corporation, a leading innovator in the early detection of Alzheimer's Disease through a non-invasive eye test, today announced that it has closed the first approximately $4 Million tranche of a Series C funding round, as the company continues clinical development of its diagnostic platform.

10 Jan 2011

EffRx submits EX101 NDA for osteoporosis treatment to FDA

EffRx Pharmaceuticals SA, a Lausanne, Switzerland based drug delivery company announces the NDA submission of the company's lead project to the US Food and Drug Administration.

10 Jan 2011

Manhattan enters settlement and release agreement with Nordic and H Pharmaceuticals

Manhattan Pharmaceuticals, Inc. announced that on January 4, 2011, the company entered into a settlement and release agreement with Nordic Biotech Fund II K/S and H Pharmaceuticals K/S. Manhattan Pharmaceuticals and Nordic are partners in the H Pharmaceuticals joint venture for the development and commercialization of Hedrin®, a non-pesticide treatment for head lice.

10 Jan 2011

Hutchinson Technology commences tender/exchange offer of 3.25% Convertible Subordinated Notes

Hutchinson Technology Incorporated today announced that it has commenced an offer to exchange or purchase, at the election of each holder and subject to the limitations described below, up to $75,294,000 of its 3.25% Convertible Subordinated Notes due 2026 (the "Old Notes").

10 Jan 2011

DATATRAK awarded Phase III device study by new European client

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded a Phase III device study by a new European client, a leading global healthcare supplier.

10 Jan 2011

SonoSite fourth quarter revenue increases 27% to $89 million

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced preliminary revenue results for the fourth quarter and year ended December 31, 2010.

10 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

Emergent BioSolutions estimates total revenue of $285 to $288 million for 2010

Emergent BioSolutions Inc. announced today preliminary, unaudited financial results for 2010 and guidance for 2011.

10 Jan 2011

Align and Cadent enter joint software development agreement for Invisalign treatment

Align Technology, Inc. and Cadent, Inc., today announced an agreement to jointly develop software applications that will run on Cadent iTero and iOC scanners for use in Invisalign treatment. The new applications will optimize case assessment and planning for Invisalign treatment, and bring valuable digital tools chair-side for Invisalign providers who use Cadent scanners.

10 Jan 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Pennsaid fourth quarter prescriptions increase 20% sequentially

Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.

10 Jan 2011

New, paid prescriptions for Questcor's Acthar increase 66%

Questcor Pharmaceuticals, Inc. today reported a strong finish to 2010. The Company estimates that 353 new, paid Acthar prescriptions for the treatment of multiple sclerosis (MS) were filled and shipped during the quarter, up 66% from the year ago period and up 9% from the third quarter of 2010.

10 Jan 2011

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).

10 Jan 2011